
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly and Co. reported strong performance in Q2 2025, exceeding expectations on both revenue and earnings while raising full-year guidance, signaling robust operational growth. Sales of the obesity treatment Mounjaro saw remarkable international growth of 60% quarter-over-quarter, and projections indicate continued strong sales growth and a significant increase in earnings per share by 2026. Additionally, the anticipated launch of orforglipron, an oral GLP-1 treatment, is expected to enhance the market for diabetes and obesity medications, further solidifying Eli Lilly's competitive position in its key therapeutic areas.
Bears say
Eli Lilly and Co faces significant downside risks that could negatively impact its stock performance, primarily due to potential pricing and rebate pressures which could compress profit margins. The company is experiencing a worse-than-expected prescription trajectory for tirzepatide, with its failure to demonstrate cardiac outcome benefits in key patient groups further complicating its commercial prospects. Additionally, the anticipated negative impact on Zepbound prescriptions and the increasing competition from orforglipron, which poses a threat to its market share, contribute to a bearish outlook on the company's financial health.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares